Trial Profile
A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anaemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 19 May 2014 New trial record
- 22 May 2008